Q3 Highlights

• Sales up 115% to $29.1M

• Continued gain in US Market Share

• Gross profit margin 41% (Negative impact of US $ vs. EURO exchange rate on European ARA Production

• Additional Infant Formula Licensees and Product Launches

• Net income greater than $4.5M

Previous slide

Next slide

Back to first slide

View graphic version